Bridging the nutrition guidance gap for GLP-1 receptor agonist therapy assisted weight loss: Lessons from bariatric surgery
Open accessAbstract
Glucagon-like peptide-1 receptor agonists and combination incretin medications (hereafter referred to as GLP-1 RAs) represent a paradigm shift in the management of obesity, approaching weight loss outcomes comparable to bariatric surgery [ 1 , 2 ]. Despite global utilisation, there remain critical clinical and research gaps in structured nutritional guidance for their use. These gaps present a clinical concern, since GLP-1 RA-induced weight loss mirrors several physiological effects of bariatric interventions, potentially resulting in significant reductions in lean mass, micronutrient depletion, altered eating behaviours, gastrointestinal symptoms, and gallstone formation [ 3 ].
AI snapshot
Written from the paper’s full text.
TL;DR
This commentary argues that GLP-1 receptor agonist (GLP-1 RA) therapy for weight loss reproduces many nutritional risks of bariatric surgery (lean mass loss, micronutrient depletion, altered eating behaviour, GI symptoms, gallstones) but lacks the structured nutritional care that accompanies surgery. The authors call for international GLP-1 RA-specific nutrition guidelines and prospective studies, drawing on post-bariatric dietary frameworks as an interim model.
Key findings
- GLP-1 RAs produce up to 22.5% mean weight loss at 72 weeks, but an estimated 30–40% of weight lost may derive from fat-free mass — a particular concern in older adults and those with sarcopenic obesity. Proposed protein targets, borrowed from bariatric protocols, are 0.8–1.6 g/kg/d or 80–120 g/day, though the authors note no prospective studies establish optimal amounts.
- Micronutrient risk (iron, B12, vitamin D, calcium, thiamine) arises from reduced intake and dietary variety rather than malabsorption; unlike bariatric surgery, no formal pre-treatment screening consensus exists for GLP-1 RA initiators. A once-daily complete multivitamin/mineral supplement is offered as a pragmatic interim strategy, with monitoring proposed every 6 months.
- Gallstones occur in 10–30% of post-bariatric patients, and similar rapid-weight-loss trajectories suggest comparable susceptibility with GLP-1 RAs; moderate fat intake, hydration, fibre, and consideration of ursodeoxycholic acid in high-risk cases are proposed.
- GLP-1 RAs are typically prescribed with minimal nutritional oversight, whereas post-bariatric care includes dietitian-led follow-up and routine biochemical surveillance; behavioural nutrition support (including COM-B-informed approaches and attention to "food noise") is described as currently non-standard.
Methods
Narrative expert commentary/perspective, not a systematic review; references were "selected through expert consensus based on relevance to obesity pharmacotherapy and post-bariatric models of care." The core output is a comparative table mapping nutritional parameters (lean mass, micronutrients, food preferences, GI symptoms, gallstones, monitoring) across bariatric surgery mechanisms, GLP-1 RA mechanisms, and bariatric-derived strategies, based on BOMSS guidance and cited clinical literature. No primary data, sample, or formal analysis is reported.
Limitations
Stated by the paper: there is a lack of prospective studies to determine optimal protein amounts during GLP-1 RA use; the longer-term psychological and behavioural impacts following medication cessation remain poorly understood; no global consensus framework exists for dietary screening, intervention, or supplementation; and implementation is constrained by limited access to registered dietitians, lack of reimbursement for nutritional counselling, and structural inequities. Evident from the text: the recommendations are extrapolated from post-bariatric protocols rather than GLP-1 RA-specific evidence, and the reference base was assembled by expert consensus rather than a systematic search, so selection bias cannot be excluded.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
0 of 24 cited sources checked · 0 supported · 0 flagged
- Premisecitation
The longer-term psychological and behavioural impacts following GLP-1 RA cessation remain poorly understood.
“Behavioural strategies may improve eating behaviours, dietary quality and adherence during GLP-1 RA use, although the longer-term psychological and behavioural impacts following medication cessation remain poorly understood and warrant further investigation [11].”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [11] Wadden TA, Chao AM, Tronieri JS. Berkowitz RI. The role of lifestyle modification with second-generation anti-obesity medications: comparisons, questions, and clinical implications. Curr Obes Rep. 2023;12:453–473. https://doi.org/10.1007/s13679-023-00534-z. source
Not checked in the free run.
- Premisecitation
Structured nutritional follow-up, including regular dietary reviews and biochemical monitoring, is a hallmark of post-bariatric care.
“Structured nutritional follow-up, including regular dietary reviews and biochemical monitoring, is a hallmark of post-bariatric care [7].”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [7] Parretti H, O’Kane M, Hughes C, Abbott S, Coulman K, Mears R et al. BOMSS post-bariatric surgery nutritional guidance for GPs. British Obesity & Metabolic Surgery Society. Available from: https://bomss.org/bomss-post-bariatric-surgery-nutritional-guidance-for-gps/. (2023). Accessed 28 Oct 2025.
Not checked in the free run.
- Premisecitation
Preoperative screening for micronutrient deficiencies is standard practice in bariatric surgery.
“Unlike bariatric surgery, where preoperative screening for micronutrient deficiencies is standard practice [6], no formal consensus recommendations currently exist for individuals commencing GLP-1 RAs.”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [6] Gudzune KA, Huizinga MM, Chang HY, Asamoah V, Gadgil M, Clark JM. Screening and diagnosis of micronutrient deficiencies before and after bariatric surgery. Obes Surg. 2013;23:1581–1589. https://doi.org/10.1007/s11695-013-0919-x. source
Not checked in the free run.
- Premisecitation
Gallstones occur in 10-30% of patients post-bariatric surgery.
“Gallstones occur in 10-30% of patients post-bariatric surgery [14]”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [14] Dai Y, Luo B, Li W. Incidence and risk factors for cholelithiasis after bariatric surgery: a systematic review and meta-analysis. Lipids Health Dis. 2023;22:139 https://doi.org/10.1186/s12944-023-01774-7. source
Not checked in the free run.
- Interpretationreasoning
Similar trajectories in GLP-1 RA-induced weight loss suggest comparable susceptibility to gallstones.
“similar trajectories in GLP-1 RA-induced weight loss suggest comparable susceptibility.”
Quote in the paperNot a substantial claim- Rests on an assumption: Rapid weight loss, irrespective of mechanism, increases the risk of gallstone formation due to gallbladder stasis and cholesterol supersaturation.
- Premisecitation
Trials show up to 22.5% mean weight loss at 72 weeks with GLP-1 RAs.
“GLP-1 RAs suppress appetite and reduce food cravings, with trials showing up to 22.5% mean weight loss at 72 weeks [1].”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [1] Brown A, Mellor D, Makaronidis J, Shuttlewood E, Miras AD, Pournaras DJ. From evidence to practice” Insights from the multidisciplinary team on the optimal integration of GLP-1 receptor agonists in obesity management services. Nutr Bull. 2024;49:257–263. https://doi.org/10.1111/nbu.12700. source
Not checked in the free run.
- Interpretationreasoning
Without proactive monitoring, clinicians may fail to identify emerging deficiencies or suboptimal intake, particularly in patients receiving therapy outside specialist care settings.
“Without proactive monitoring, clinicians may fail to identify emerging deficiencies or suboptimal intake, particularly in patients receiving therapy outside specialist care settings.”
Quote in the paperSubstantial claim- Rests on an assumption: GLP-1 RAs are typically administered with minimal ongoing nutritional oversight.
- Premisecitation
An estimated 30-40% of weight lost during GLP-1 RA therapy may derive from fat-free mass.
“an estimated 30–40% of weight lost may derive from fat-free mass, which is of particular concern for older adults and individuals with sarcopenic obesity [4, 5].”
Quote in the paperSubstantial claim0 of 2 sources checked- cites [4] Prado CMM, Wells JCK, Smith SR, Stephan BCM, Siervo M. Sarcopenic obesity: a critical appraisal of the current evidence. Clin Nutr. 2012;31:583–601. https://doi.org/10.1016/j.clnu.2012.06.010. source
Not checked in the free run.
- cites [5] Villareal DT, Apovian CM, Kushner RF, Klein S. American Society for Nutrition; NAASO, The Obesity Society. Obesity in older adults: technical review and position statement of the American Society for Nutrition and NAASO, The Obesity Society. Am J Clin Nutr. 2005;82:923–934. source
Not checked in the free run.
- Premisecitation
Protein intake ranges of 0.8-1.6 g/kg/d or 80-120 g/day have been proposed for GLP-1 RA users, similar to those proposed for bariatric surgery.
“ranges between 0.8–1.6 g/kg/d or absolute protein amounts (80–120 g/day), similar to those proposed for bariatric surgery, have been proposed [8].”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [8] Mozaffarian D, Agarwal M, Aggarwal M, Alexander L, Apovian CM, Bindlish S, et al. Nutritional priorities to support GLP-1 therapy for obesity: a joint advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society. Obesity. 2025;33:1475–1503. https://doi.org/10.1002/oby.24336. source
Not checked in the free run.
- Premisecitation
Recent publications have begun to address nutritional considerations for obesity management medication treatment.
“Recent publications have begun to address nutritional considerations for obesity management medication treatment [8, 10]”
Quote in the paperNot a substantial claim0 of 2 sources checked- cites [8] Mozaffarian D, Agarwal M, Aggarwal M, Alexander L, Apovian CM, Bindlish S, et al. Nutritional priorities to support GLP-1 therapy for obesity: a joint advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society. Obesity. 2025;33:1475–1503. https://doi.org/10.1002/oby.24336. source
Not checked in the free run.
- cites [10] Butsch WS, Sulo S, Chang AT, Kim JA, Kerr KW, Williams DR, et al. Nutritional deficiencies and muscle loss in adults with type 2 diabetes using GLP-1 receptor agonists: a retrospective observational study. Obes Pillars. 2025;15:100186. https://doi.org/10.1016/j.obpill.2025.100186. source
Not checked in the free run.
- Premisecitation
The potential risk of micronutrient insufficiencies with GLP-1 RAs remains considerable due to low oral intake that may be nutritionally inadequate.
“the potential risk of micronutrient insufficiencies remains considerable due to low oral intake that may be nutritionally inadequate, as supported by recently published evidence [10].”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [10] Butsch WS, Sulo S, Chang AT, Kim JA, Kerr KW, Williams DR, et al. Nutritional deficiencies and muscle loss in adults with type 2 diabetes using GLP-1 receptor agonists: a retrospective observational study. Obes Pillars. 2025;15:100186. https://doi.org/10.1016/j.obpill.2025.100186. source
Not checked in the free run.
- Premisecitation
GLP-1 RA-induced weight loss mirrors several physiological effects of bariatric interventions.
“GLP-1 RA-induced weight loss mirrors several physiological effects of bariatric interventions, potentially resulting in significant reductions in lean mass, micronutrient depletion, altered eating behaviours, gastrointestinal symptoms, and gallstone formation [3].”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [3] Arterburn DE, Telem DA, Kushner RF, Courcoulas AP. Benefits and risks of bariatric surgery in adults: a review. JAMA. 2020;324:879–887. https://doi.org/10.1001/jama.2020.12567. source
Not checked in the free run.
- Interpretationreasoning
Behavioural adaptations from GLP-1 RA use could lead to suboptimal dietary quality.
“These behavioural adaptations, while partially responsible for weight loss, could lead to suboptimal dietary quality.”
Quote in the paperNot a substantial claim - Premisecitation
Nausea, vomiting, and constipation are commonly encountered side effects associated with GLP-1 RA use, particularly during dose titration and at higher doses.
“Nausea, vomiting, and constipation are commonly encountered side effects associated with GLP-1 RA use, particularly during dose titration and at higher doses [1].”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [1] Brown A, Mellor D, Makaronidis J, Shuttlewood E, Miras AD, Pournaras DJ. From evidence to practice” Insights from the multidisciplinary team on the optimal integration of GLP-1 receptor agonists in obesity management services. Nutr Bull. 2024;49:257–263. https://doi.org/10.1111/nbu.12700. source
Not checked in the free run.
- Interpretationreasoning
There remain critical clinical and research gaps in structured nutritional guidance for GLP-1 RA use.
“Despite global utilisation, there remain critical clinical and research gaps in structured nutritional guidance for their use.”
Quote in the paperSubstantial claim - Premisecitation
Patients frequently report a reduction in intrusive food-related thoughts during GLP-1 RA use, referred to as food noise.
“patients frequently report a reduction in intrusive food-related thoughts during GLP-1 RA use, referred to in some literature as ‘food noise’, recently defined and measured using a validated questionnaire [12].”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [12] Diktas HE, Cardel MI, Foster GD, LeBlanc MM, Dickinson SL, Ables EM, et al. Development and validation of the Food Noise Questionnaire. Obesity. 2025;33:289–297. https://doi.org/10.1002/oby.24216. source
Not checked in the free run.
- Premisecitation
Behavioural strategies may improve eating behaviours, dietary quality and adherence during GLP-1 RA use.
“Behavioural strategies may improve eating behaviours, dietary quality and adherence during GLP-1 RA use, although the longer-term psychological and behavioural impacts following medication cessation remain poorly understood and warrant further investigation [11].”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [11] Wadden TA, Chao AM, Tronieri JS. Berkowitz RI. The role of lifestyle modification with second-generation anti-obesity medications: comparisons, questions, and clinical implications. Curr Obes Rep. 2023;12:453–473. https://doi.org/10.1007/s13679-023-00534-z. source
Not checked in the free run.
- May combine two claims. 8
- Classified as probably not a substantial claim. 3
May combine two claims.
PremisecitationPatients using GLP-1 RAs may experience changes in eating behaviour, including reduced hunger, fewer food cravings, and a decrease in binge eating, food noise, emotional eating, and uncontrolled eating.
“Patients using GLP-1 RAs may experience changes in eating behaviour, including reduced hunger, fewer food cravings, and a decrease in binge eating, ‘food noise’, emotional eating, and uncontrolled eating [1].”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [1] Brown A, Mellor D, Makaronidis J, Shuttlewood E, Miras AD, Pournaras DJ. From evidence to practice” Insights from the multidisciplinary team on the optimal integration of GLP-1 receptor agonists in obesity management services. Nutr Bull. 2024;49:257–263. https://doi.org/10.1111/nbu.12700. source
Not checked in the free run.
May combine two claims.
PremisecitationGLP-1 receptor agonists and combination incretin medications are a paradigm shift in obesity management, with weight loss outcomes approaching those of bariatric surgery.
“Glucagon-like peptide-1 receptor agonists and combination incretin medications (hereafter referred to as GLP-1 RAs) represent a paradigm shift in the management of obesity, approaching weight loss outcomes comparable to bariatric surgery [1, 2].”
Quote in the paperSubstantial claim0 of 2 sources checked- cites [1] Brown A, Mellor D, Makaronidis J, Shuttlewood E, Miras AD, Pournaras DJ. From evidence to practice” Insights from the multidisciplinary team on the optimal integration of GLP-1 receptor agonists in obesity management services. Nutr Bull. 2024;49:257–263. https://doi.org/10.1111/nbu.12700. source
Not checked in the free run.
- cites [2] Almandoz JP, Wadden TA, Tewksbury C, Apovian CM, Fitch A, Ard JD, et al. Nutritional considerations with anti-obesity medications. Obesity. 2024;32:1613–1631. https://doi.org/10.1002/oby.24067. source
Not checked in the free run.
May combine two claims.
PremisecitationLoss of skeletal muscle can impair metabolic health, diminish physical function, and compromise weight maintenance.
“Loss of skeletal muscle can impair metabolic health, diminish physical function, and compromise weight maintenance [6].”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [6] Gudzune KA, Huizinga MM, Chang HY, Asamoah V, Gadgil M, Clark JM. Screening and diagnosis of micronutrient deficiencies before and after bariatric surgery. Obes Surg. 2013;23:1581–1589. https://doi.org/10.1007/s11695-013-0919-x. source
Not checked in the free run.
May combine two claims.
PremisecitationGLP-1 RAs suppress appetite and reduce food cravings.
“GLP-1 RAs suppress appetite and reduce food cravings, with trials showing up to 22.5% mean weight loss at 72 weeks [1].”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [1] Brown A, Mellor D, Makaronidis J, Shuttlewood E, Miras AD, Pournaras DJ. From evidence to practice” Insights from the multidisciplinary team on the optimal integration of GLP-1 receptor agonists in obesity management services. Nutr Bull. 2024;49:257–263. https://doi.org/10.1111/nbu.12700. source
Not checked in the free run.
Classified as probably not a substantial claim. May combine two claims.
InterpretationreasoningDietary adaptations such as favouring dry, low-fat foods during nausea, increasing fibre and fluid intake may support treatment adherence.
“Dietary adaptations such as favouring dry, low-fat foods during periods of nausea, increasing fibre and fluid intake may support treatment adherence.”
Quote in the paperSubstantial claimClassified as probably not a substantial claim.
PremisecitationThe COM-B model can support the identification of psychological and contextual factors influencing behaviour.
“Behaviour change frameworks such as the Capability, Opportunity, Motivation, Behaviour (COM-B) model can support the identification of psychological and contextual factors influencing behaviour [13].”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [13] Michie S, van Stralen MM, West R. The behaviour change wheel: a new method for characterising and designing behaviour change interventions. Implement Sci. 2011;6:42 https://doi.org/10.1186/1748-5908-6-42. source
Not checked in the free run.
May combine two claims.
InterpretationreasoningThe absence of a global consensus framework for GLP-1 RA nutrition can lead to heterogeneity in clinical practice and may expose patients to preventable complications.
“This void can lead to heterogeneity in clinical practice and may expose patients to preventable complications.”
Quote in the paperSubstantial claim- Rests on an assumption: There remains no global consensus framework for dietary screening, intervention, or supplementation for GLP-1 RA users.
May combine two claims.
PremisecitationEarly satiety, nausea, and changes in food preferences often result in reduced dietary variety and diminished intake of essential nutrients, including iron, vitamin B12, vitamin D, calcium, and thiamine.
“Early satiety, nausea, and changes in food preferences often result in reduced dietary variety and diminished intake of essential nutrients, including iron, vitamin B12, vitamin D, calcium, and thiamine [6, 9].”
Quote in the paperSubstantial claim0 of 2 sources checked- cites [6] Gudzune KA, Huizinga MM, Chang HY, Asamoah V, Gadgil M, Clark JM. Screening and diagnosis of micronutrient deficiencies before and after bariatric surgery. Obes Surg. 2013;23:1581–1589. https://doi.org/10.1007/s11695-013-0919-x. source
Not checked in the free run.
- cites [9] Kushner RF, Batsis JA, Butsch WS, Davis N, Golden A, Halperin F, et al. Weight history in clinical practice: the state of the science and future directions. Obesity. 2020;28:9–17. https://doi.org/10.1002/oby.22642. source
Not checked in the free run.
Probably not a substantial claim: may not pass S4 (based).
Premisenone givenThe physiological consequences of rapid weight loss, including lean mass loss, micronutrient deficiencies, altered eating behaviours, gastrointestinal symptoms, and gallstones, are well-documented.
“The physiological consequences of rapid weight loss, including lean mass loss, micronutrient deficiencies, altered eating behaviours, gastrointestinal symptoms, and gallstones, are well-documented.”
Quote in the paperNot a substantial claimMay combine two claims.
PremisecitationSmall, frequent meals, slow eating, and fluid separation may help mitigate GLP-1 RA gastrointestinal symptoms.
“Drawing on post-bariatric strategies, small, frequent meals, slow eating, and fluid separation may help mitigate symptoms [7].”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [7] Parretti H, O’Kane M, Hughes C, Abbott S, Coulman K, Mears R et al. BOMSS post-bariatric surgery nutritional guidance for GPs. British Obesity & Metabolic Surgery Society. Available from: https://bomss.org/bomss-post-bariatric-surgery-nutritional-guidance-for-gps/. (2023). Accessed 28 Oct 2025.
Not checked in the free run.
The paper relies on this without support.
There is a lack of prospective studies to determine optimal protein amounts for GLP-1 RA users.
“Presently, there is a lack of prospective studies to determine optimal protein amounts”
The paper relies on this without support.
GLP-1 RAs do not induce malabsorption.
“Although GLP-1 RAs do not induce malabsorption”
The paper relies on this without support.
No formal consensus recommendations currently exist for individuals commencing GLP-1 RAs.
“no formal consensus recommendations currently exist for individuals commencing GLP-1 RAs.”
The paper relies on this without support.
Behavioural nutrition support is currently not standard practice when prescribing GLP-1 RAs.
“Behavioural nutrition support is currently not standard practice when prescribing GLP-1 RAs”
The paper relies on this without support.
Pragmatic dietary strategies for GLP-1 RA gastrointestinal symptoms are currently inconsistently communicated to patients and remain absent from current GLP-1 RA care models.
“These pragmatic strategies, however, are currently inconsistently communicated to patients and remain absent from current GLP-1 RA care models.”
The paper relies on this without support.
Rapid weight loss, irrespective of mechanism, increases the risk of gallstone formation due to gallbladder stasis and cholesterol supersaturation.
“Rapid weight loss, irrespective of the mechanism, increases the risk of gallstone formation due to gallbladder stasis and cholesterol supersaturation.”
The paper relies on this without support.
GLP-1 RAs are typically administered with minimal ongoing nutritional oversight.
“GLP-1 RAs are typically administered with minimal ongoing nutritional oversight.”
The paper relies on this without support.
There remains no global consensus framework for dietary screening, intervention, or supplementation for GLP-1 RA users.
“there remains no global consensus framework for dietary screening, intervention, or supplementation for GLP-1 RA users.”
Cites
Michie, S., van Stralen, M. M., & West, R. (2011) · Implementation Science · doi:10.1186/1748-5908-6-42 · Cited by 13,697 · see citing works
Benefits and Risks of Bariatric Surgery in Adults: A Review
Arterburn, D. E., Telem, D. A., Kushner, R. F., & Courcoulas, A. P. (2020) · JAMA · doi:10.1001/jama.2020.12567 · Cited by 1,251 · see citing works
Villareal, D. T., Apovian, C. M., Kushner, R. F., & Klein, S. (2005) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/82.5.923 · Cited by 880 · see citing works
Sarcopenic obesity: a critical appraisal of the current evidence
Prado, C. M. M., Wells, J. C. K., Smith, S. R., Stephan, B. C. M., & Siervo, M. (2012) · Clinical Nutrition · doi:10.1016/j.clnu.2012.06.010 · Cited by 589 · see citing works
Mozaffarian, D., Agarwal, M., Aggarwal, M., Alexander, L., Apovian, C. M., Bindlish, S., Bonnet, J., Butsch, W. S., Christensen, S., Gianos, E., et al. (2025) · Obesity · doi:10.1002/oby.24336 · Cited by 143 · see citing works
Nutritional considerations with antiobesity medications
Almandoz, J. P., Wadden, T. A., Tewksbury, C., Apovian, C. M., Fitch, A., Ard, J. D., Li, Z., Richards, J., Butsch, W. S., Jouravskaya, I., et al. (2024) · Obesity · doi:10.1002/oby.24067 · Cited by 134 · see citing works
Wadden, T. A., Chao, A. M., Moore, M., Tronieri, J. S., Gilden, A., Amaro, A., Leonard, S., & Jakicic, J. M. (2023) · Current Obesity Reports · doi:10.1007/s13679-023-00534-z · Cited by 129 · see citing works
Screening and Diagnosis of Micronutrient Deficiencies Before and After Bariatric Surgery
Gudzune, K. A., Huizinga, M. M., Chang, H.-Y., Asamoah, V., Gadgil, M., & Clark, J. M. (2013) · Obesity Surgery · doi:10.1007/s11695-013-0919-x · Cited by 109 · see citing works
Scott Butsch, W., Sulo, S., Chang, A. T., Kim, J. A., Kerr, K. W., Williams, D. R., Hegazi, R., Panchalingam, T., Goates, S., & Heymsfield, S. B. (2025) · Obesity Pillars · doi:10.1016/j.obpill.2025.100186 · Cited by 58 · see citing works
Weight History in Clinical Practice: The State of the Science and Future Directions
Kushner, R. F., Batsis, J. A., Butsch, W. S., Davis, N., Golden, A., Halperin, F., Kidambi, S., Machineni, S., Novick, M., Port, A., et al. (2020) · Obesity · doi:10.1002/oby.22642 · Cited by 55 · see citing works
Dai, Y., Luo, B., & Li, W. (2023) · Lipids in Health and Disease · doi:10.1186/s12944-023-01774-7 · Cited by 35 · see citing works
Development and validation of the Food Noise Questionnaire
Diktas, H. E., Cardel, M. I., Foster, G. D., LeBlanc, M. M., Dickinson, S. L., Ables, E. M., Chen, X., Nathan, R., Shapiro, D., & Martin, C. K. (2025) · Obesity · doi:10.1002/oby.24216 · Cited by 35 · see citing works
Brown, A., Mellor, D., Makaronidis, J., Shuttlewood, E., Miras, A. D., & Pournaras, D. J. (2024) · Nutrition Bulletin · doi:10.1111/nbu.12700 · Cited by 9 · see citing works
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Dobbie, L. J., Tolvanen, L., Alves, D., Baker, J. L., Bez, N. S., Birney, S., Bogl, L. H., Brown, A., Bullo, M., Clare, K., et al. (2026) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(26)00122-1 · Cited by 8 · see citing works
Self-citationZambrano-Villacres, R., Campuzano-Donoso, M., Reytor-González, C., Rossetti, G., Cobellis, L., Cobellis, F., Pilone, V., Simancas‐Racines, D., & Schiavo, L. (2026) · Nutrients · doi:10.3390/nu18111751 · Cited by 7 · see citing works
Griffiths, A., Gregory, S., Malcomson, F. C., Spreckley, M., Matu, J., Ells, L. J., & Shannon, O. M. (2026) · International Journal of Obesity · doi:10.1038/s41366-026-02190-4 · Cited by 4 · see citing works
Self-citationSimancas‐Racines, D., Campuzano-Donoso, M., Rossetti, G., Cobellis, L., Pilone, V., Fascì-Spurio, F., Gavilanes, D. J., Soria, C., Reytor-González, C., & Schiavo, L. (2026) · Obesity Pillars · doi:10.1016/j.obpill.2026.100290 · Cited by 3 · see citing works
Rutigliani, G., & Mattes, R. D. (2026) · Physiology & Behavior · doi:10.1016/j.physbeh.2026.115486 · Cited by 4 · see citing works
Griffiths, A., Shannon, O. M., Spreckley, M., Austin, K., Fallows, E., Clare, K., Ells, L. J., & Matu, J. (2025) · medRxiv · doi:10.64898/2025.12.11.25342052 · Cited by 3 · see citing works
Self-citationMaida, C. D., Scaglione, S., Norrito, R. L., Daidone, M., Pacinella, G., Marchese, A., Vutano, F., Cassataro, G., Dell’Ajra, L., Ferrantelli, S., et al. (2026) · Nutrients · doi:10.3390/nu18101592 · Cited by 2 · see citing works
GLP-1 Receptor Agonists in Periodontology: Mechanisms, Clinical Evidence, and Implications for Care
Șufaru, I.-G., Vasiliu, B. C., Hăncianu, M., Stratul, Ş., Tatarciuc, M., Iovan, G., Tatarciuc, D., Rudnic, I., Hanu, D., Paduraru, S., et al. (2026) · Biomolecules · doi:10.3390/biom16060857 · Cited by 5 · see citing works
Dumitru, C. N., Marcu, T., Dumitru, A. O., Tudor, S. S., Ferțu, I. D., Elisei, A.-M., & Goroftei, L. (2026) · Pharmaceuticals · doi:10.3390/ph19081313 · Cited by 2 · see citing works
Yoon, Y., Hwang, J., Yang, C. C.-K., Moon, M., Lee, J.-J., Lam, K. H. S., de Castro, J. C., Suryadi, T., Suhaimi, A., & Lee, J.-J. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27146287 · Cited by 1 · see citing works
Mallardo, M., Messina, A., Monda, V., Marra, M. L., Monda, A., Allocca, S., Casillo, M., Maio, G. D., Perrone, P., Daniele, A., et al. (2026) · Nutrients · doi:10.3390/nu18172748 · Cited by 1 · see citing works
Korbela, J., & Białek, A. (2026) · Nutrients · doi:10.3390/nu18050742
Soni, R., Goswami, D., Gani, A., Halami, P. M., & Chauhan, K. (2026) · Current Obesity Reports · doi:10.1007/s13679-026-00729-0
Tan, A. S. H., Saafan, T. S. M., Ashoush, F., & Mahawar, K. K. (2026) · World Journal of Clinical Cases · doi:10.12998/wjcc.121701
Kataria, S., Pylypiv, O., & Fahrenkrog, M. C. (2026) · A&A Practice · doi:10.1213/xaa.0000000000002253
Joshi, S., Misra, A., Mithal, A., Saboo, B., Seshadri, K., Chowdhury, S., Bantwal, G., Sethi, B. K., Kesavadev, J., Bhattacharya, A. D., et al. (2026) · Obesity Pillars · doi:10.1016/j.obpill.2026.100296
Ming, Q., & Li, Z. (2026) · Frontiers in Nutrition · doi:10.3389/fnut.2026.1914155
Sorić, T., Sarić, A., Ivanišin, A., Lovrić, M., Milić, M., Matovinović, M., & Sarić, M. M. (2026) · Nutrients · doi:10.3390/nu18172757
Hungund, S. (2026) · Qeios · doi:10.32388/i85yu1
Cook, G. (2026) · Journal of Medical Internet Research · doi:10.2196/104227
Marino, F., Savo, M. T., Cozac, D. A., Galzerano, D., Sabah, M. E., Cordoni, G., Tansella, D., Palmisano, M., Kholaif, N., Mohty, D., et al. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15197428
́ópez, S. G. L., Cataño, S., Pérez-Lalinde, S., & Reyes, D. (2026) · Dermatologic Therapy · doi:10.1155/dth/5742100
GLP-1 revolution and future of food systems: Current evidence, emerging trends, & projected impacts
Munialo, C. D. (2026) · Food and Humanity · doi:10.1016/j.foohum.2026.101569
- Authors
- Spreckley, M., Ruggiero, C. F., & Brown, A.
- Affiliations
- University of Cambridge (GB)
- University College Hospital (GB)
- Corresponding author
- Brown, Adrian
- Venue
- International Journal of Obesity
- Published
- 2025-11-15
- Volume
- 50
- Issue
- 2
- Pages
- 265-267
- ISSN
- 0307-0565 (ISSN-L)
- 1476-5497
- PMC
- PMC12913018
- OpenAlex
- W4416247778
- Semantic Scholar
- 882d53beacd396fefdae6321981494557483bf77
- Cited by
- 22
- References
- 13
- Citations by year
- 2026: 21 · 2025: 1
- FWCI
- 20.70
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- International Journal of Obesity (publishedVersion, cc-by)
- PubMed (publishedVersion)
- PubMed Central (publishedVersion, cc-by)
- UCL Discovery (University College London) (submittedVersion)
- Apollo (University of Cambridge) (submittedVersion, cc-by)
- Funders
- National Institute for Health and Care Research
- Medical Research Council (MC_ UU_00006/6)
- Topics
- Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
- Health Sciences › Medicine › Pharmacology › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- GLP-1 receptor agonists, obesity, weight loss, dietary recommendations, bariatric surgery, incretin-based therapy, lean body mass, micronutrient depletion, eating behaviour, gastrointestinal symptoms, gallstone formation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Claims read by deepseek-v4.1-flash under definition version 3 (extract-v3) on 2026-10-08.
Classified by jev-1.13-20260917 (gold-guideline-v0.2) on 2026-10-08.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
